SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S20 - Neuromyelitis Optica and Other Autoimmune Disorders

Event Time: Tuesday April 25, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
2:35 PM - 3:00 PM Discussion Dean Wingerchuk MD, FAAN 

Disclosures

Speaker Disclosure
Dean M. Wingerchuk, MD, FAAN Dr. Wingerchuk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Caladrius and MedImmune. Dr. Wingerchuk has received personal compensation in an editorial capacity for The Neurologist.. Dr. Wingerchuk has received research support from Alexion and TerumoBCT.

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Justification for New Diagnostic Criteria for Susac Syndrome: Evolving Beyond the Triad Robert Carruthers, MD
Disclosure:
Dr. Carruthers has received personal compensation for activities with Roche, Novartis, Biogen, Genzyme and Teva as a consultant/speaker. Dr. Carruthers has received research support from Teva.

1:12 PM 002 Specificity of glial fibrillary acidic protein IgG autoantibody (GFAP-IgG) for Autoimmune Meningoencephalomyelitis Diagnosis Eoin Flanagan, MBBCh
Disclosure:
Dr. Flanagan has nothing to disclose.

1:24 PM 003 Pathophysiological impact of anti-AMPA receptor antibodies in autoimmune encephalitis Holger Haselmann
Disclosure:
Dr. Geis has nothing to disclose.

1:36 PM 004 IgLON5 Autoimmunity: Serological Findings, Neurological Disorders & Outcomes in 16 patients Josephe Archie Honorat
Disclosure:
Dr. Honorat has nothing to disclose.

1:48 PM 005 Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders Maureen Mealy, RN,BSN, MSCN
Disclosure:
Dr. Mealy has received personal compensation for activities with Consortium of Multiple Sclerosis Centers as a speaker.

2:00 PM 006 Placental transmission of AQP4-IgG to neonate from mothers with neuromyelitis optica spectrum disorder (NMOSD) Jessica Sagen
Disclosure:
Dr. Sagen has nothing to disclose.

2:12 PM 007 Aquaporin-4 antibody titration in NMO patients treated with Rituximab: a retrospective study. Antonio Bertolotto, MD
Disclosure:
Dr. Bertolotto received personal compensation for activities with Almirall, Biogen, Merck, Novartis, Sanofi Genzye, and TEVA as a speaker and/or consultant. Dr. Bertolotto has received research support from Biogen, Merck, Novartis, and TEVA.

2:24 PM 008 Central Dysregulation of Heart Rate and Blood Pressure in Autoimmune AQP4 Channelopathy: Expanding the neuromyelitis optica spectrum disorder (NMOSD). Masoud Majed
Disclosure:
Dr. Majed has nothing to disclose.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C98 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C108 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C122 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C162 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C175 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C224 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?